Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

35 36 Next >

A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation ↗

May 03, 2024

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

Via Investor's Business Daily

Teva to Present at the 2024 Bank of America Healthcare Conference

May 02, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

May 02, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know ↗

March 08, 2024

Via Benzinga

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗

May 01, 2024

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...

Via Benzinga

Topics Intellectual Property

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

April 30, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

April 30, 2024

From Alvotech

Via GlobeNewswire

US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz ↗

April 22, 2024

"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."

Via Benzinga

Topics Intellectual Property

Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23 ↗

April 17, 2024

The Israel-Hamas War has only adversely affected the stock returns of 6 of the 15 small cap Israeli- domiciled companies listed on U.S. exchanges but, In total, their returns have exceeded those of...

Via Talk Markets

Topics Stocks

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

April 16, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

April 16, 2024

From Alvotech

Via GlobeNewswire

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

April 16, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

April 11, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

April 09, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead ↗

April 08, 2024

Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks.

Via The Motley Fool

Topics Artificial Intelligence

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

April 06, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

April 04, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

3 No-Brainer Stocks to Buy With $600 Right Now ↗

April 03, 2024

A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.

Via The Motley Fool

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

April 01, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In' ↗

March 25, 2024

Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer.

Via Benzinga

Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗

March 21, 2024

GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...

Via Benzinga

The Generic Drugs Antitrust Case ↗

March 16, 2024

Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of...

Via Talk Markets

Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗

March 02, 2024

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...

Via Talk Markets

Drug Maker Organon Stock Scores Relative Strength Upgrade ↗

February 28, 2024

In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.

Via Investor's Business Daily

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 26, 2024

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 26, 2024

Via Benzinga

Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000? ↗

February 26, 2024

Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000.

Via InvestorPlace

Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock ↗

February 26, 2024

Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning.

Via InvestorPlace

TEVA Stock Pops 4% as Teva Receives FDA Approval ↗

February 26, 2024

Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.

Via InvestorPlace

Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? ↗

February 26, 2024

FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.